Pharmalink makes board appointments
This article was originally published in Scrip
Executive Summary
The privately held Swedish speciality pharmaceutical company Pharmalink has appointed Anders Wiklund and Dr Jens Christensen to its board of directors. Mr Wiklund has been an advisor to the biotechnology industry since 1997, when he founded Wiklund International. Dr Kristensen is vice-president of clinical development at the Swedish drug development company KaroBio. In addition, Dr Lennart Hansson, director of the life sciences business area at Industrifonden, an independent foundation founded in 1979, joins Pharmalink's board as the Industrifonden representative. Dr Hansson, who has experience in the life science sector having worked at KabiGen, Symbicom, AstraZeneca, Arexis, Biovitrum and Karolinska Development, replaces retiring board member Professor Jörgen Lönngren.